Perthera is proud to have supported the advancement of clinical research efforts by providing physicians and clinical researchers the Precision Medicine Platform. The results of these publications have demonstrated increased OS and PFS patient survival rates, and have uncovered novel mutations that have been significant in treatment decision making.
The Lancet Oncology – Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial (March 2nd, 2020)
Surgical Oncology – A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution’s experience (February 8th, 2020)
JCO Precision Oncology – Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program (October 23rd, 2019)
Oncotarget – Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations (October 22nd, 2019)
JAMIA Open – A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients (October 7th, 2019)
British Journal of Oncology – Multi-Omic Molecular Comparison of Primary vs. Metastatic Pancreatic Tumors (July 11th, 2019)
JCO Precision Oncology – Entrectinib in TRK and ROS1 Fusion-Positive Metastatic Pancreatic Cancer (July 25th, 2018)
Cancer Biology & Therapy – Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer (March 6th, 2018)
JCO Precision Oncology – Anaplastic Lymphoma Kinase Rearrangement and Response to Crizotinib in Pancreatic Ductal Adenocarcinoma (August 7th, 2017)